Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2022 Oct;20(10):2448.
doi: 10.1111/jth.15845.

Corrigendum

No authors listed
Published Erratum

Corrigendum

No authors listed. J Thromb Haemost. 2022 Oct.
No abstract available

PubMed Disclaimer

Figures

FIGURE 2
FIGURE 2
Effects of asundexian versus rivaroxaban on thrombus weight following FeCl2 ‐induced damage to the carotid artery (A), ear bleeding time (B) and gum bleeding time (C) in rabbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity (E) and aPTT prolongation (F) according to asundexian dose, and correlation of plasma concentrations (G), Inhibition of FXIa activity (%) (H), and aPTT prolongation (I) with thrombus weight. Asundexian was administered as an intravenous bolus, whereas rivaroxaban was administered as an intravenous bolus followed by continuous infusion. Results are presented as individual values and median with 25th and 75th percentiles (Parts A–F). *p < .05, ***p < .001. aPTT, activated partial thromboplastin time; FXIa, activated coagulation factor XI.
See this image and copyright information in PMC

Erratum for

References

    1. Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor Xia. J Thromb Haemost. 2022;20(6):1400‐1411. doi:10.1111/jth.15700 - DOI - PMC - PubMed

Publication types